4Conter LO,Shymanski J,Ramotar K,et al.Impact and cost ofinfection control measures to reduce nosocomial transmissionof extendedspectrumb-lactamase-producing organisms in anon-outbreak setting[J].J Hosp Infect,2007,65(4):354-360.
5Harbarth S,Fankhauser C,Schrenzel J,et al.Universal screeningfor methicillin-resistant Staphylococcus aureus at hospital admis-sion and no socomial infection in surgical patients[J].JAMA,2008,299(10):1149.
6Tacconelli E.Sereening and isolation for infection control[J].J Hosp Infect,2009,5(2):1-7.
8Voss A,Milatovic D,Wallrauch-Schwarz C. Methicillinresistant Staphylococcus aureus in Europe[J].European Journal of Clinical Microbiology and Infectious Diseases,1994,(01):50-55.
9Tiernersma EW,Bronzwaer SL,Lyytikāinen O. Methicillin-resistant Staphylococcus aureus in Europe,1999-2002[J].Emerging Infectious Diseases,2004,(09):1627-1634.
10Johnson AP,Pearson A,Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK[J].Journal of Antimicrobial Chemotherapy,2005,(03):455-462.
9Harbarth S,Fankhauser C.Schrenzd J, etal. Universul screen-ing for methicilHn-resistangt Staphylococcus aureus at hospitaladmission and no socomial infetian in surgical patitents [J].JAMA,2008,299(10) :1149.
